Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis

American Journal of Pathology

Volumn 177, Issue 3, 2010, Pages 1214-1224

  Moles, Anna ^a,b   Tarrats, Núria ^a,b   Morales, Albert ^a,b   Domínguez, Marlene ^a   Bataller, Ramón ^a   Caballería, Juan ^a   García Ruiz, Carmen ^a,b   Fernández Checa, José C ^a,b,c   Marí, Montserrat ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INST D INVESTIGACIONS B   (Spain)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA ACTIN; CARBON TETRACHLORIDE; CATHEPSIN B; CATHEPSIN D; MESSENGER RNA; SMALL INTERFERING RNA; SPHINGOMYELIN PHOSPHODIESTERASE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE DUCT LIGATION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FIBROGENESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER FIBROSIS; LIVER INJURY; MALE; MOUSE; MYOFIBROBLAST; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; STELLATE CELL; WILD TYPE;

EID: 77956519382     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091257     Document Type: Article

References (52)

1. Iredale JP: Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007, 117:539-548
2. Friedman SL: Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008, 88:125-172
3. Tsukada S, Parsons CJ, Rippe RA: Mechanisms of liver fibrosis. Clin Chim Acta 2006, 364:33-60
4. Brunt EM: Nonalcoholic steatohepatitis. Semin Liver Dis 2004, 24:3-20
5. Bugianesi E, Leone N, Vanni E: Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140 (Pubitemid 34747534)
6. Clark JM, Diehl AM: Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003, 289:3000-3004 (Pubitemid 37430103)
7. Erickson SK: Nonalcoholic fatty liver disease. J Lipid Res 2009, 50:S412-S416
8. Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005, 115:209-218
9. Gressner AM: Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int 1996, 54:S39-S45
10. Kisseleva T, Brenner DA: Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006, 21:S84-S87 (Pubitemid 44266558)
11. Hannun YA, Obeid LM: Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008, 9:139-150
12. Morales A, Lee H, Goñi FM, Kolesnick R, Fernández-Checa JC: Sphingolipids and cell death. Apoptosis 2007, 12:923-939
13. Liu YY, Yu JY, Yin D, Patwardhan GA, Gupta V, Hirabayashi Y, Holleran WM, Giuliano AE, Jazwinski SM, Gouaze-Andersson V, Consoli DP, Cabot MC: A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J 2008, 22:2541-2551 (Pubitemid 351948671)
14. Grassmé H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Kolesnick R, Gulbins E: CD95 signaling via ceramide-rich membrane rafts. J Biol Chem 2001, 276:20589-20596 (Pubitemid 37411145)
15. Grassmé H, Cremesti A, Kolesnick R, Gulbins E: Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 2003, 22:5457-5470 (Pubitemid 37072201)
16. Krönke M: Biophysics of ceramide signaling: interaction with proteins and phase transition of membranes. Chem Phys Lipids 1999, 101:109-121
17. Schuchman EH, Suchi M, Takahashi T, Sandhoff K, Desnick RJ: Human acid sphingomyelinase. Isolation, nucleotide sequence and expression of the full-length and alternatively spliced cDNAs. J Biol Chem 1991, 266:8531-8539 (Pubitemid 21906542)
18. Smith EL, Schuchman EH: Acid sphingomyelinase overexpression enhances the antineoplastic effects of irradiation in vitro and in vivo. Mol Ther 2008, 16:1565-1571
19. Grassmé H, Jendrossek V, Riehle A, von Kürthy G, Berger J, Schwarz H, Weller M, Kolesnick R, Gulbins E: Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 2003, 9:322-330 (Pubitemid 36362788)
20. Becker KA, Gellhaus A, Winterhager E, Gulbins E: Ceramide-enriched membrane domains in infectious biology and development. Subcell Biochem 2008, 49:523-538
21. Schütze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Krönke M: TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 1992, 71:765-776
22. Wiegmann K, Schütze S, Machleidt T, Witte D, Krönke M: Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 1994, 78:1005-1015 (Pubitemid 24292328)
23. Cifone MG, Roncaioli P, De Maria R, Camarda G, Santoni A, Ruberti G, Testi R: Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J 1995, 14:5859-5868
24. Liu P, Anderson RG: Compartmentalized production of ceramide at the cell surface. J Biol Chem 1995, 270:27179-27185
25. García-Ruiz C, Colell A, Marí M, Morales A, Calvo M, Enrich C, Fernández-Checa JC: Defective TNF-α-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J Clin Invest 2003, 111:197-208
26. Marí M, Colell A, Morales A, Pañeda C, Varela-Nieto I, García-Ruiz C, Fernández-Checa JC: Acidic sphingomyelinase downregulates the liver- specific methionine adenosyltransferase 1A, contributing to tumor necrosis factor-induced lethal hepatitis. J Clin Invest 2004, 113:895-904
27. Smith EL, Schuchman EH: The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J 2008, 22:3419-3431
28. Heinrich M, Wickel M, Schneider-Brachert W, Sandberg C, Gahr J, Schwandner R, Weber T, Saftig P, Peters C, Brunner J, Krönke M, Schütze S: Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J 1999, 8:5252-5263 (Pubitemid 29465576)
29. Heinrich M, Neumeyer J, Jakob M, Hallas C, Tchikov V, Winoto- Morbach S, Wickel M, Schneider-Brachert W, Trauzold A, Hethke A, Schütze S: Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ 2004, 11:550-563 (Pubitemid 38660140)
30. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, Kaufmann SH, Gores GJ: Cathepsin B contributes to TNF-α- mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000, 106:1127-1137
31. Moles A, Tarrats N, Fernández-Checa JC, Marí M: Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology 2009, 49:1297-1307
32. Institute of Laboratory Animal Resources: Guide for the Care and Use of Laboratory Animals, 7th ed. Washington, DC, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, 1996
33. Llacuna L, Marí M, Garcia-Ruiz C, Fernández-Checa JC, Morales A: Critical role of acidic sphingomyelinase in murine hepatic ischemiareperfusion injury. Hepatology 2006, 44:561-572 (Pubitemid 44433712)
34. Jamall IS, Finelli VN, Que Hee SS: A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981, 112:70-75
35. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ: Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321
36. -ΔΔCt. Method Methods 2001, 5:402-408
37. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ: Human hepatic stellate cell lines. LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005, 54:142-151
38. Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E: Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem 2008, 51:219-237
39. Takashima T, Kawada N, Maeda N, Okuyama H, Uyama N, Seki S, Arakawa T: Pepstatin A attenuates the inhibitory effect of N-acetyl-L-cysteine on proliferation of hepatic myofibroblasts (stellate cells). Eur J Pharmacol 2002, 451:265-270 (Pubitemid 35254029)
40. Okuyama H, Shimahara Y, Kawada N, Seki S, Kristensen DB, Yoshizato K, Uyama N, Yamaoka Y: Regulation of cell growth by redox-mediated extracellular proteolysis of platelet-derived growth factor receptor β. J Biol Chem 2001, 276:28274-28280 (Pubitemid 37391534)
41. Osawa Y, Seki E, Adachi M, Suetsugu A, Ito H, Moriwaki H, Seishima M, Nagaki M: Role of acid sphingomyelinase of Kupffer cells in cholestatic liver injury in mice. Hepatology 2010, 51:237-845
42. Langmann T, Buechler C, Ries S, Schaeffler A, Aslanidis C, Schuierer M, Weiler M, Sandhoff K, de Jong PJ, Schmitz G: Transcription factors Sp1 and AP-2 mediate induction of acid sphingomyelinase during monocytic differentiation. J Lipid Res 1999, 40:870-880 (Pubitemid 29220528)
43. Murate T, Suzuki M, Hattori M, Takagi A, Kojima T, Tanizawa T, Asano H, Hotta T, Saito H, Yoshida S, Tamiya-Koizumi K: Up-regulation of acid sphingomyelinase during retinoic acid-induced myeloid differentiation of NB4, a human acute promyelocytic leukemia cell line. J Biol Chem 2002, 277:9936-9943 (Pubitemid 34968100)
44. Santana P, Peña LA, Haimovitz-Friedman A, Martin S, Green D, McLoughlin M, Cordon-Cardo C, Schuchman EH, Fuks Z, Kolesnick R: Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996, 86:189-199 (Pubitemid 26286102)
45. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rübben H, Schmid KW, Mann K, Hilden-brand S, Hefter H, Huber SM, Wieder T, Erhardt A, Häussinger D, Gulbins E, Lang F: Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007, 13:164-170 (Pubitemid 46245766)
46. Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW, Weller M, Tümmler B, Lang F, Grassme H, Döring G, Gulbins E: Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008, 14:382-391 (Pubitemid 351499396)
47. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM: Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 2005, 11:491-498 (Pubitemid 40685971)
48. Sommerfeld A, Reinehr R, Haussinger D: Bile acid-induced EGFR activation in quiescent rat hepatic stellate cells can trigger both, proliferation and apoptosis. J Biol Chem 2009, 284:22173-22183
49. Schuchman EH: The pathogenesis and treatment of acid sphingomyelinase- deficient Niemann-Pick disease. J Inherit Metab Dis 2007, 30:654-663
50. Marathe S, Miranda SR, Devlin C, Johns A, Kuriakose G, Williams KJ, Schuchman EH, Tabas I: Creation of a mouse model for non-neurological (type B) Niemann-Pick disease by stable, low level expression of lysosomal sphingomyelinase in the absence of secretory sphingomyelinase: relationship between brain intra-lysosomal enzyme activity and central nervous system function. Hum Mol Genet 2000, 9:1967-1976 (Pubitemid 30642661)
51. Gupta S, Natarajan R, Payne SG, Studer EJ, Spiegel S, Dent P, Hylemon PB: Deoxycholic acid activates the c-Jun N-terminal kinase pathway via FAS receptor activation in primary hepatocytes. Role of acidic sphingomyelinase-mediated ceramide generation in FAS receptor activation. J Biol Chem 2004, 279:5821-5828 (Pubitemid 38220613)
52. Canbay A, Guicciardi ME, Higuchi H, Feldstein A, Bronk SF, Rydzewski R, Taniai M, Gores GJ: Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest 2003, 112:152-159 (Pubitemid 38056351)